Correlation of Serum Decoy Receptor 3 and Interleukin-6 with Severity of Coronary Artery Diseases in Acute Myocardial Infarction Patients DcR3 in myocardial infarction

Main Article Content

Hossein Doustkami
Leli Avesta
Behzad Babapour
Mohammad Hossein Boskabady
Ali Nikoukhesal
Mohammad Reza Aslani


Decoy receptor 3; epicardial fat thickness; echocardiography; acute myocardial infarction


Background: Decoy receptor 3 (DcR3), is a soluble receptor which is thought to have immune modulator or pro-inflammatory effects. Various risk factors have been suggested for the incidence of cardiovascular diseases (CADs) such as an increase in inflammatory factors. The purpose of the present study was to investigate the correlation of DcR3 with anthropometric, angiographic, echocardiographic, and biochemical parameters in patients with acute myocardial infarction.

Methods and Materials: A total of 90 patients who were candidates for angiography were included in the study and were divided into three groups: 30 patients with acute myocardial infarction (AMI), 30 patients with stable angina pectoris (SAP), and 30 subjects as control group with a history of chest pain but normal angiography. Anthropometric, angiographic, echocardiographic, and biochemical parameters were measured in all subjects.

Results: Serum DcR3 and interleukin (IL)-6 levels were significantly increased in patients with AMI compared with SAP and control groups (P < 0.05 to P < 0.001). In addition, there was a positive association between serum level of DcR3 and epicardial fat thickness (EFT), Gensini score, creatine kinase (CK)-MB, IL-6, and white blood cell (WBC) count in CAD patients. The results of multivariate linear regression analysis revealed that WBC count and IL-6 levels were independently associated with serum DcR3 levels.

Conclusion:  The current study showed an association of DcR3 and IL-6, WBC count, EFT, CK-MB, and Gensini score for the first time in AMI patients. Increased DcR3 levels in patients with AMI may be involved in the process of atherosclerosis.


Download data is not yet available.
Abstract 78 |


1. Lin W-W, Hsieh S-L. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 2011;81 (7): 838-47.
2. Cheng CP, Sytwu HK, Chang DM. Decoy receptor 3 attenuates collagen-induced arthritis by modulating T cell activation and B cell expansion. J Rheumatol 2011;38 (12): 2522-35.
3. Chang YC, Hsu TL, Lin HH, Chio CC, Chiu AW et al. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004;75 (3): 486-94.
4. Mueller AM, Pedré X, Killian S, David M, Steinbrecher A. The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol 2009;209 (1): 57-64.
5. Hung SC, Hsu TW, Lin YP, Tarng DC. Decoy receptor 3, a novel inflammatory marker, and mortality in hemodialysis patients. Clin J Am Soc Nephrol 2012;7 (8): 1257-65.
6. Yang C-R, Hsieh S-L, Ho F-M, Lin W-W. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-κB-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J Immunol 2005;174 (3): 1647-56.
7. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25 (6): 1256-61.
8. Xiu Z, Shen H, Tian Y, Xia L, Lu J. Serum and synovial fluid levels of tumor necrosis factor-like ligand 1A and decoy receptor 3 in rheumatoid arthritis. Cytokine 2015;72 (2): 185-9.
9. Chen C-Y, Yang K-Y, Chen M-Y, Chen H-Y, Lin M-T et al. Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Am J Respir Crit Care Med 2009;180 (8): 751-60.
10. Chen M-H, Kan H-T, Liu C-Y, Yu W-K, Lee S-S et al. Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients. J Formos Med Assoc 2017;116 (1): 49-56.
11. Cardinale CJ, Wei Z, Panossian S, Wang F, Kim CE et al. Targeted resequencing identifies defective variants of decoy receptor 3 in pediatric-onset inflammatory bowel disease. Genes Immun 2013;14 (7): 447-52.
12. Soliman MH, Ebaid AM. Association of Tumor Necrosis Like factor 1 A (TL1A) and its Decoy Receptor (DcR3) with The Disease Activity and Autoantibody Production in Rheumatoid Arthritis Patients. Egypt J Immunol 2019;26 (1): 43-54.
13. Lee CS, Hu CY, Tsai HF, Wu CS, Hsieh SL et al. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol 2008;151 (3): 383-90.
14. Funke B, Autschbach F, Kim S, Lasitschka F, Strauch U et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009;58 (4): 483-91.
15. Gao L, Yang B, Zhang H, Ou Q, Lin Y et al. DcR3, a new biomarker for sepsis, correlates with infection severity and procalcitonin. Oncotarget 2018;9 (13): 10934-44.
16. Yamada D, Asano Y, Takahashi T, Masui Y, Aozasa N et al. Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis. Eur J Dermatol 2012;22 (3): 351-7.
17. Dong Y, Shi D, Li M, Dai P, Wang X, Xie M. Elevated serum levels of decoy receptor 3 are associated with disease severity in patients with hemorrhagic fever with renal syndrome. Intern Emerg Med 2015;10 (5): 567-73.
18. Ghobadi H, Hosseini N, Aslani MR. Correlations Between Serum Decoy Receptor 3 and Airflow Limitation and Quality of Life in Male Patients with Stable Stage and Acute Exacerbation of COPD. Lung 2020.
19. Chang TY, Hsu CY, Huang PH, Chiang CH, Leu HB et al. Usefulness of Circulating Decoy Receptor 3 in Predicting Coronary Artery Disease Severity and Future Major Adverse Cardiovascular Events in Patients With Multivessel Coronary Artery Disease. Am J Cardiol 2015;116 (7): 1028-33.
20. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29 (4): 277-314.
21. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 2003;11 (2): 304-10.
22. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 2009;22 (12): 1311-9; quiz 417-8.
23. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990;119 (6): 1262-7.
24. Okazaki S, Sakaguchi M, Miwa K, Furukado S, Yamagami H et al. Association of Interleukin-6 With the Progression of Carotid Atherosclerosis. Stroke 2014;45 (10): 2924-29.
25. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111 (25): 3481-88.
26. Chang YC, Hsu TL, Lin HH, Chio CC, Chiu AW et al. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004;75 (3): 486-94.
27. Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc Res 2000;45 (3): 736-46.
28. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95 (3): 594-9.
29. Kim S, McAuliffe WJ, Zaritskaya LS, Moore PA, Zhang L, Nardelli B. Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. Infect Immun 2004;72 (1): 89-93.
30. Ohashi K, Shibata R, Murohara T, Ouchi N. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab 2014;25 (7): 348-55.
31. Akhavanakbari G, Babapour B, Alipour MR, Keyhanmanesh R, Ahmadi M, Aslani MR. Effect of high fat diet on NF‐кB microRNA146a negative feedback loop in ovalbumin‐sensitized rats. Biofactors 2019;45 (1): 75-84.
32. Keyhanmanesh R, Alipour MR, Ebrahimi H, Aslani MR. Effects of Diet-Induced Obesity on Tracheal Responsiveness to Methacholine, Tracheal Visfatin Level, and Lung Histological Changes in Ovalbumin-Sensitized Female Wistar Rats. Inflammation 2018;41 (3): 846-58.
33. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108 (20): 2460-6.
34. Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006;5: 1.
35. Ortiz A, Lorz C, Justo P, Catalan MP, Egido J. Contribution of apoptotic cell death to renal injury. J Cell Mol Med 2001;5 (1): 18-32.